Company intelligence / Profile preview

Broaden Biopharma

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Broaden Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to address infectious diseases and oncology. Its lead programs include mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV), as well as innovative mRNA-encoded protein therapies for cancer. Broaden Biopharma aims to provide high-quality, accessible mRNA solutions through its integrated R&D and manufacturing capabilities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Drug pipeline

1 asset

BB-TME

Preclinical

Beyond the preview

Go deeper on Broaden Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Broaden Biopharma.

Explore the full profile